|
|
Article: Development of a Novel ^sup 99m^Tc-Chelate-Conjugated Bisphosphonate with High Affinity for Bone as a Bone Scintigraphic Agent
- Article from:
- The Journal of Nuclear Medicine
- Article date:
- December 1, 2006
- Author:
CopyrightCopyright Society of Nuclear Medicine Dec 2006. Provided by ProQuest LLC. (Hide copyright information)
|
In bone scintigraphy using ^sup 99m^Tc with methylenediphosphonate (^sup 99m^Tc-MDP) and hydroxymethylenediphosphonate (^sup 99m^Tc-HMDP), it takes 2-6 h after an injection before imaging can start. This interval could be shortened with a new radiopharmaceutical with higher affinity for bone. Here, based on the concept of bifunctional radiopharmaceuticals, we designed a ^sup 99m^Tc-mercaptoacetylglycylglycylglycine (MAG3)-conjugated hydroxy-bisphosphonate (HBP) (^sup 99m^Tc-MAG3-HBP) and a ^sup 99m^Tc-6-hydrazinopyridine-3-carboxylic acid (HYNIC)-conjugated hydroxy-bisphosphonate (^sup 99m^Tc-HYNIC-HBP). Methods: ^sup 99m^Tc-MAG3-HBP was prepared by complexation of MAG3-HBP with ^sup 99m^Tc ...